Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1
Science Advances · 2026
DOI: 10.1126/sciadv.aeg9953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Xin Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Adenocarcinoma of Lung, Mutation. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, National Science Foundation of China.
Abstract (Originalsprache)
The efficacy of immune checkpoint blockade (ICB) in lung adenocarcinoma (LUAD) is limited by primary or acquired resistance, especially in genetically defined subsets. We investigated the impact of KRAS/TP53 co-mutation on ICB response. Our analysis reveals that KRAS/TP53 co-mutation is associated with favorable ICB outcomes, a phenotype orchestrated by secreted phosphoprotein 1 (SPP1). Mechanistically, mutant p53 and KRAS exert opposing effects on SPP1. Mutant p53 synergizes with transcription factor FOXA1 to repress SPP1 transcription, whereas KRAS activates the mitogen-activated protein kinase (MAPK)–extracellular signal–regulated kinase (ERK)–signal transducer and activator of transcription 1 (STAT1) axis to up-regulate SPP1 . Consequently, reduced SPP1 level in KRAS/TP53 co-mutant LUAD impairs myeloid-derived suppressor cell (MDSC) recruitment and increases CD8+ T cell infiltration. Notably, SPP1 blockade synergizes with anti–programmed death-1 (PD-1) therapy to suppress tumor growth in KRAS -mutant xenograft models. Collectively, we delineate a mutant p53–FOXA1–SPP1 regulatory axis that modulates ICB susceptibility and unveil a synergistic combination therapy strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Institute of Thoracic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
ORCID-Profile: Xin Zhang, Qian Hao, Wenyue Yang, Yunbo Yu, Qingya Yan, Zhihuang Hu, Xiang Zhou, Jialei Wang
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- National Science Foundation of China
- Shanghai Municipal Science and Technology Project
- Beijing Life Oasis Public Service Center
- Collaborative Innovation Cluster Program of Shanghai Municipal Health Commission
- Shanghai Leading Talent Program of Eastern Talent Plan
Zitieren
APA
Zhang, X., Hao, Q., Yang, W., Yu, Y., Yan, Q., Wu, Z., Hu, Z., Zhou, X., & Wang, J. (2026). Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science Advances. https://doi.org/10.1126/sciadv.aeg9953
Vancouver
Zhang X, Hao Q, Yang W, Yu Y, Yan Q, Wu Z, et al. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science Advances. 2026. doi:10.1126/sciadv.aeg9953
BibTeX
@article{Zhang2026,
author = {Zhang, Xin and Hao, Qian and Yang, Wenyue and Yu, Yunbo and Yan, Qingya and Wu, Zhenhua and Hu, Zhihuang and Zhou, Xiang and Wang, Jialei},
title = {Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeg9953}
}
EUVIMED